IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback